Apomorphine intranasal - Britannia

Drug Profile

Apomorphine intranasal - Britannia

Latest Information Update: 09 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Britannia Pharmaceuticals
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Erectile dysfunction; Parkinson's disease

Most Recent Events

  • 30 May 2007 Apomorphine-intranasal is available for licensing for male erectile dysfunction worldwide (http://www.britannia-pharm.co.uk/partnerships.shtml)
  • 30 May 2007 Apomorphine-intranasal is available for licensing for PD worldwide, excluding the UK and North America (http://www.britannia-pharm.co.uk/partnerships.shtml)
  • 23 Jan 2004 Clinical data from a media release have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top